{'fraction_non_alphanumeric': 0.04766839378238342, 'fraction_numerical': 0.024870466321243522, 'mean_word_length': 5.355263157894737, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Evaluation of Kryptor cardiac troponin I immunoassay

Background and Methods: Cardiac troponin I (cTnI) is well recognized as a specific marker for myocardial infarction. A fully automated, random access, fluorescent immunoassay for cTnI was evaluated in comparison with an established assay (Stratus cTnI) using samples from healthy subjects and from patients with cardiac disease. Results: The detection and precision were acceptable, and no interference was observed from bilirubin, triglycerides, haemoglobin, rheumatoid factor, drugs (aspirin, dopamine, digoxin) or heparin. Results on the Kryptor cTnI assay correlated with those on the Stratus II cTnI assay. The optimum Kryptor cTnI concentration for acute myocardial infarction was 0.63 µg/L, with a sensitivity of 89% [95% confidence interval (CI): 75.9-96.3] and specificity of 98.9% (95% CI: 93.9-99.8). Conclusion: Kryptor cTnI immunoassay is suitable for use in the diagnosis of myocardial infarction.